PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14668580-3	2004	Omapatrilat, a VasoPeptidase-inhibitor, selectively inhibits both Neutral-Endo-Peptidase (NEP) and ACE.	omapatrilat	0-11	membrane metallo endopeptidase	Mus musculus	66-88	
14668580-3	2004	Omapatrilat, a VasoPeptidase-inhibitor, selectively inhibits both Neutral-Endo-Peptidase (NEP) and ACE.	omapatrilat	0-11	membrane metallo endopeptidase	Mus musculus	90-93	
12745671-0	2003	Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient mice.	omapatrilat	0-11	membrane metallo endopeptidase	Mus musculus	50-71	
12745671-1	2003	Omapatrilat inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP).	omapatrilat	0-11	membrane metallo endopeptidase	Mus musculus	66-87	
12745671-1	2003	Omapatrilat inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP).	omapatrilat	0-11	membrane metallo endopeptidase	Mus musculus	89-92	
34304582-2	2021	Omapatrilat, a dual NEP inhibitor-ACE inhibitor, was a promising antihypertensive drug but failed in trials due to angioedema, an effect possibly caused by inhibition of both the N- and C-domains of ACE.	omapatrilat	0-11	membrane metallo endopeptidase	Mus musculus	20-23	
16208151-13	2005	By contrast, in the kidney, local renal ACE and NEP inhibition and the superior antihypertensive effect of omapatrilat all contribute to the renoprotective effect conferred by omapatrilat treatment in the diabetic apo E-KO mouse.	omapatrilat	176-187	membrane metallo endopeptidase	Mus musculus	48-51